The Valley Desk

Clinical trial reportLancet (London, England)Published

Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Lancet (London, England)
Published
Subject terms
Humans; Crohn Disease; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method; Adult; Middle Aged; Female; Male; Young Adult; Antibodies, Monoclonal, Humanized; Maintenance Chemotherapy
PubMed ID
40684778
Added to directory
Source checked

Report a correction or request removal